| pubmed-article:2185793 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C0031858 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C1521970 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C1516451 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C1514623 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C1512612 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C0084044 | lld:lifeskim |
| pubmed-article:2185793 | lifeskim:mentions | umls-concept:C0752549 | lld:lifeskim |
| pubmed-article:2185793 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2185793 | pubmed:dateCreated | 1990-6-14 | lld:pubmed |
| pubmed-article:2185793 | pubmed:abstractText | Phytohemagglutinin retains the properties of a theoretically ideal biologic response modifier in that it is available in a purely mitogenic L4 isolectin form that is stable; previously studied extensively; applicable as a simple skin test to assess immune competence and guide therapy; broadly immunostimulating with respect to both activation and proliferation of effector cell pathways; amenable to targeting maneuvers; stimulative of endogenous cytokine production; conveniently administrable by multiple routes; applicable to both active and adoptive immunotherapies; rapidly interacting irreversibly with lymphocytes; readily applied as a vaccine adjuvant; apparently nonsensitizing; relatively nontoxic, with maximum effective levels well below those for major toxicity; free from stress induction; nononcogenic; noninfectious; related to other mitogenic lectins that have augmenting therapeutic potential; compatible with other therapeutic modalities and conductive to collaborative use of other BRMs; well-suited to application as a surgical adjuvant and for prophylaxis against malignancies or infections in susceptible individuals; applicative to debilitated, immunosuppressed, and myelosuppressed patients; probably compatible with pregnancy; and potentially cost-effective. | lld:pubmed |
| pubmed-article:2185793 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2185793 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2185793 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2185793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2185793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2185793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2185793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2185793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2185793 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2185793 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:2185793 | pubmed:issn | 0952-8172 | lld:pubmed |
| pubmed-article:2185793 | pubmed:author | pubmed-author:WimerB MBM | lld:pubmed |
| pubmed-article:2185793 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2185793 | pubmed:volume | 2 | lld:pubmed |
| pubmed-article:2185793 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2185793 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2185793 | pubmed:pagination | 4-17 | lld:pubmed |
| pubmed-article:2185793 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:meshHeading | pubmed-meshheading:2185793-... | lld:pubmed |
| pubmed-article:2185793 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2185793 | pubmed:articleTitle | Characteristics of PHA-L4, the mitogenic isolectin of phytohemagglutinin, as an ideal biologic response modifier. | lld:pubmed |
| pubmed-article:2185793 | pubmed:affiliation | Department of Medicine, Texas Tech University School of Medicine, Lubbock. | lld:pubmed |
| pubmed-article:2185793 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2185793 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2185793 | lld:pubmed |
